UY29458A1 - Heterociclos sustituidos y usos de los mismos - Google Patents
Heterociclos sustituidos y usos de los mismosInfo
- Publication number
- UY29458A1 UY29458A1 UY29458A UY29458A UY29458A1 UY 29458 A1 UY29458 A1 UY 29458A1 UY 29458 A UY29458 A UY 29458A UY 29458 A UY29458 A UY 29458A UY 29458 A1 UY29458 A1 UY 29458A1
- Authority
- UY
- Uruguay
- Prior art keywords
- heterocicles
- replaced
- same
- novel compounds
- pfdk1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La invención se refiere compuestos novedosos de fórmula (I) y a sus composiciones farmacéuticas y sus métodos de utilización. Dichos compuestos novedosos presentan actividad inhibitoria de las quinasa CHK1, PFDK1 y Pak y son por lo tanto útiles en el tratamiento y/o profilaxis de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66877905P | 2005-04-06 | 2005-04-06 | |
US73886605P | 2005-11-21 | 2005-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29458A1 true UY29458A1 (es) | 2006-11-30 |
Family
ID=36586532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29458A UY29458A1 (es) | 2005-04-06 | 2006-04-06 | Heterociclos sustituidos y usos de los mismos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090275570A1 (es) |
EP (1) | EP1869052A1 (es) |
JP (1) | JP2008534664A (es) |
KR (1) | KR20080009200A (es) |
AR (1) | AR053352A1 (es) |
AU (1) | AU2006232620A1 (es) |
BR (1) | BRPI0608659A2 (es) |
CA (1) | CA2601983A1 (es) |
IL (1) | IL186112A0 (es) |
MX (1) | MX2007012448A (es) |
NO (1) | NO20074634L (es) |
RU (1) | RU2007140734A (es) |
TW (1) | TW200714604A (es) |
UY (1) | UY29458A1 (es) |
WO (1) | WO2006106326A1 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
ATE553108T1 (de) * | 2005-11-08 | 2012-04-15 | Hoffmann La Roche | Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors |
WO2007062318A2 (en) * | 2005-11-18 | 2007-05-31 | Smithkline Beecham Corporation | Chemical compounds |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
US7842713B2 (en) | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
US7994321B2 (en) * | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
ES2528797T3 (es) * | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
US20080085886A1 (en) * | 2006-08-21 | 2008-04-10 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
WO2008063933A2 (en) * | 2006-11-10 | 2008-05-29 | Massachusetts Institute Of Technology | Pak modulators |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
CN101687036A (zh) * | 2007-04-27 | 2010-03-31 | 阿斯利康(瑞典)有限公司 | 治疗恶性血液病的chk1抑制剂与b细胞耗尽抗体 |
CN101678019B (zh) | 2007-06-08 | 2016-03-30 | 詹森药业有限公司 | 哌啶/哌嗪衍生物 |
US8835437B2 (en) | 2007-06-08 | 2014-09-16 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JP5464709B2 (ja) | 2007-06-08 | 2014-04-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン/ピペラジン誘導体 |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
JP5489296B2 (ja) * | 2007-12-13 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | Janusキナーゼの阻害剤 |
CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
JP5608097B2 (ja) | 2008-01-08 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピロロピリジン |
JP5608098B2 (ja) | 2008-01-09 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピラゾロピリジン |
AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
US7998688B2 (en) | 2008-03-07 | 2011-08-16 | OSI Pharmaceuticals, LLC | Inhibition of EMT induction in tumor cells by anti-cancer agents |
CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
EP2296659B1 (en) | 2008-06-05 | 2016-12-21 | Janssen Pharmaceutica, N.V. | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist |
NZ591366A (en) | 2008-09-11 | 2012-05-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
EP2177510A1 (en) * | 2008-10-17 | 2010-04-21 | Universität des Saarlandes | Allosteric protein kinase modulators |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
EP2406253B1 (en) | 2009-03-11 | 2013-07-03 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
NZ599453A (en) * | 2009-09-18 | 2014-03-28 | Zhanggui Wu | Novel compounds and therapeutic use thereof for protein kinase inhibition |
US8871765B2 (en) | 2010-07-27 | 2014-10-28 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors |
DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
US9370567B2 (en) | 2010-11-16 | 2016-06-21 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors |
RU2013126036A (ru) | 2010-11-17 | 2014-12-27 | Ф. Хоффманн-Ля Рош Аг | Способ лечения опухолей |
DE102011008352A1 (de) | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
WO2012097478A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic carboxamide inhibitors of kinases |
DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
MX2013012661A (es) | 2011-04-29 | 2014-03-27 | Amgen Inc | Compuestos de piridazina biciclicos como inhibidores pim. |
MX2014010953A (es) | 2012-03-16 | 2014-10-13 | Hoffmann La Roche | Metodos para tratamiento de melanoma con inhibidores pak1. |
DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
US9938258B2 (en) | 2012-11-29 | 2018-04-10 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
DK2938598T3 (en) | 2012-12-31 | 2017-02-13 | Cadila Healthcare Ltd | Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
HUE040645T2 (hu) * | 2013-06-26 | 2019-03-28 | Abbvie Inc | BTK-inhibitor primer karboxamidok |
KR102581373B1 (ko) | 2013-07-03 | 2023-09-20 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 치환된 벤조퓨라닐 및 벤즈옥사졸릴 화합물 및 이의 용도 |
US9994558B2 (en) | 2013-09-20 | 2018-06-12 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
EP2865757A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
DK3209656T3 (da) | 2014-10-24 | 2020-07-13 | Bristol Myers Squibb Co | Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere |
WO2016100515A1 (en) * | 2014-12-16 | 2016-06-23 | Karyopharm Therapeutics Inc. | Cyclic compounds and uses thereof |
CR20170420A (es) | 2015-03-13 | 2017-10-03 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 |
EP3325100A4 (en) | 2015-07-17 | 2019-02-20 | Memorial Sloan-Kettering Cancer Center | COMBINED THERAPY USING PDK1 AND PI3K INHIBITORS |
CN108137563A (zh) | 2015-08-18 | 2018-06-08 | 卡尔约药物治疗公司 | 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
EP3941471A4 (en) * | 2019-03-18 | 2022-11-02 | The Council of the Queensland Institute of Medical Research | CARDIOMYOCYTE PROLIFERATION |
EP4087563A4 (en) * | 2020-01-07 | 2024-03-27 | Shanghai Huayu Biotechnology Co Ltd | CANCER COMBINATION THERAPY USING A CHK INHIBITOR |
JP2024503280A (ja) * | 2020-12-29 | 2024-01-25 | レボリューション メディシンズ インコーポレイテッド | Sos1阻害剤及びその使用 |
CN113816970B (zh) * | 2021-09-18 | 2022-08-09 | 济宁医学院附属医院 | 一种选择性铜离子螯合剂、其制备方法及其在肺纤维化中的应用 |
CN113861215B (zh) * | 2021-09-18 | 2022-05-17 | 济宁医学院附属医院 | 一种选择性铜离子螯合剂、其制备方法及其在结直肠癌中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018419A2 (en) * | 2002-08-23 | 2004-03-04 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
WO2004093812A2 (en) * | 2003-04-22 | 2004-11-04 | Irm Llc | Compounds that induce neuronal differentiation in embryonic stem cells |
US20050148643A1 (en) * | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
-
2006
- 2006-04-05 CA CA002601983A patent/CA2601983A1/en not_active Abandoned
- 2006-04-05 EP EP06726646A patent/EP1869052A1/en not_active Withdrawn
- 2006-04-05 JP JP2008504840A patent/JP2008534664A/ja active Pending
- 2006-04-05 BR BRPI0608659-4A patent/BRPI0608659A2/pt not_active Application Discontinuation
- 2006-04-05 RU RU2007140734/04A patent/RU2007140734A/ru not_active Application Discontinuation
- 2006-04-05 AU AU2006232620A patent/AU2006232620A1/en not_active Abandoned
- 2006-04-05 KR KR1020077025794A patent/KR20080009200A/ko not_active Application Discontinuation
- 2006-04-05 WO PCT/GB2006/001242 patent/WO2006106326A1/en active Application Filing
- 2006-04-05 US US11/910,358 patent/US20090275570A1/en not_active Abandoned
- 2006-04-05 MX MXMX07012448A patent/MX2007012448A/es not_active Application Discontinuation
- 2006-04-06 TW TW095112162A patent/TW200714604A/zh unknown
- 2006-04-06 UY UY29458A patent/UY29458A1/es not_active Application Discontinuation
- 2006-04-06 AR ARP060101374A patent/AR053352A1/es not_active Application Discontinuation
-
2007
- 2007-09-12 NO NO20074634A patent/NO20074634L/no not_active Application Discontinuation
- 2007-09-20 IL IL186112A patent/IL186112A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006106326A8 (en) | 2007-11-29 |
AU2006232620A1 (en) | 2006-10-12 |
AR053352A1 (es) | 2007-05-02 |
MX2007012448A (es) | 2007-10-19 |
WO2006106326A1 (en) | 2006-10-12 |
NO20074634L (no) | 2007-10-31 |
KR20080009200A (ko) | 2008-01-25 |
EP1869052A1 (en) | 2007-12-26 |
JP2008534664A (ja) | 2008-08-28 |
IL186112A0 (en) | 2008-01-20 |
BRPI0608659A2 (pt) | 2010-11-30 |
US20090275570A1 (en) | 2009-11-05 |
RU2007140734A (ru) | 2009-05-20 |
TW200714604A (en) | 2007-04-16 |
CA2601983A1 (en) | 2006-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos | |
DOP2006000061A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
CR11359A (es) | Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b | |
UY31072A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
ECSP099322A (es) | Compuestos químicos | |
CU23464B7 (es) | (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
ATE502038T1 (de) | Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen | |
UY30282A1 (es) | Compuestos quimicos | |
NO20084257L (no) | Diketopiperazin og piperidin derivater som antivirale midler | |
DK1853602T3 (da) | Kemiske forbindelser | |
DK1853588T3 (da) | Kemiske forbindelser | |
ECSP077985A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
ECSP077836A (es) | Compuestos mejorados farmacocinéticamente | |
BRPI0818672A2 (pt) | 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase | |
UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
DOP2006000087A (es) | Compuestos heteroaromaticos acilaminobiciclicos y sus usos | |
NO20074414L (no) | 1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft | |
NO20054361D0 (no) | Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160810 |